Sunday, 22 July 2018

Aldeyra Therapeutics, J&J collaborate to treat Systemic Inflammatory Diseases

01 March 2018 | News

Aldeyra plans to collaborate with Janssen on the development of novel drugs designed to sequester pro-inflammatory aldehyde mediators

Aldeyra Therapeutics, Inc. a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases.

The company announced that it has entered into a collaborative research agreement with Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Aldeyra plans to collaborate with Janssen on the development of novel drugs designed to sequester pro-inflammatory aldehyde mediators, a new class of therapeutic targets.

Aldeyra's aldehyde sequestration platform represents a novel therapeutic class, led by reproxalap, a first-in-class drug candidate that has demonstrated anti-inflammatory activity in four Phase 2 clinical trials.

The agreement is intended to advance the development of existing analogs of reproxalap for the treatment of systemic inflammatory diseases.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Is Telemedicine a key component that will help bring down the disparity in health offerings between rural and urban India?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls